MedTrace Logo

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

NCT02515240 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2015-08-07

No results posted yet for this study

Summary

The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.

Conditions

  • Pneumococcal Infection

Interventions

BIOLOGICAL

PPV23

23 valent pneumococcal polysaccharide vaccine in Healthy adults.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Toledo Health Science Campus

    lead OTHER

Principal Investigators

  • Julie MA Westerink, MD · University of Toledo-HSC

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-06-30
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02515240 on ClinicalTrials.gov